It is made available under a CC-BY-NC-ND 4.0 International license .

1 Delta variants of SARS-CoV-2 cause significantly increased

2 vaccine breakthrough COVID-19 cases in Houston, Texas

- 3
- 4

•	
5	Paul A. Christensen, ^{*,†,‡} Randall J. Olsen, ^{*,†,‡} S. Wesley Long, ^{*,†,‡} Sishir Subedi, [†] James
6	J. Davis, ^{§,¶} Parsa Hodjat, [†] Debbie R. Walley, [†] Jacob C. Kinskey, [†] Matthew Ojeda
7	Saavedra, [†] Layne Pruitt, [†] Kristina Reppond, [†] Madison N. Shyer, [†] Jessica Cambric, [†]
8	Ryan Gadd, † Rashi M. Thakur, † Akanksha Batajoo, † Regan Mangham, † Sindy Pena, †
9	Trina Trinh, [†] Prasanti Yerramilli, [†] Marcus Nguyen, ^{§,¶} Robert Olson, ^{§,¶} Richard Snehal, [†]
10	Jimmy Gollihar, ^{†,#} James M. Musser, ^{†,‡,} **
11	
12	*Contributed equally;
13	[†] Laboratory of Human Molecular and Translational Human Infectious Diseases, Center
14	for Infectious Diseases, Houston Methodist Research Institute and Department of
15	Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, Texas 77030;
16	[‡] Department of Pathology and Laboratory Medicine, Weill Cornell Medical College,
17	1300 York Avenue, New York City, New York 10065;
18	$^{\$}$ Consortium for Advanced Science and Engineering, 22 University of Chicago, 5801
19	South Ellis Avenue, Chicago, Illinois, 60637;

- ²⁰ [¶]Computing, Environment and Life Sciences, Argonne National Laboratory, 9700 South
- 21 Cass Avenue, Lemont, Illinois, 60439;
- ²² [#]DEVCOM Army Research Laboratory-South, Austin, Texas 78712
- 23
- ^{**}Address correspondence to James M. Musser, M.D., Ph.D., Department of Pathology
- 25 and Genomic Medicine, Houston Methodist Research Institute, 6565 Fannin Street,
- 26 Suite B490, Houston, Texas 77030. Tel: 713.441.5890, E-mail:
- 27 jmmusser@houstonmethodist.org
- 28
- 29 Running head: Delta variants and vaccine breakthrough
- 30
- 31 Disclosures: None.
- 32
- 33 Number of text pages: 15
- 34 Number of tables: 3
- 35 Number of figures: 4
- 36
- 37 Funding: This project was supported by the Houston Methodist Academic Institute
- 38 Infectious Diseases Fund; and supported in whole or in part with federal funds from the
- 39 National Institute of Allergy and Infectious Diseases, National Institutes of Health,
- 40 Department of Health and Human Services, under Contract No. 75N93019C00076
- 41 (J.J.D. and R.O.).

It is made available under a CC-BY-NC-ND 4.0 International license .

42 Abstract

43 Genetic variants of SARS-CoV-2 have repeatedly altered the course of the COVID-19 pandemic. Delta variants of concern are now the focus of intense international attention 44 45 because they are causing widespread COVID-19 disease globally and are associated with vaccine breakthrough cases. We sequenced the genomes of 12,221 SARS-CoV-2 46 from samples acquired March 15, 2021 through August 26, 2021 in the Houston 47 Methodist hospital system. This sample represents 88% of all Methodist system COVID-48 49 19 patients during the study period. Delta variants increased rapidly from late April onward to cause 99.7% of all COVID-19 cases and spread throughout the Houston 50 51 metroplex. Compared to other variants, Delta caused a significantly higher rate of vaccine breakthrough cases (23.4% compared to 6.2% for all other variants combined). 52 Importantly, significantly fewer fully vaccinated individuals required hospitalization. 53 54 Individuals with vaccine breakthrough cases caused by Delta had a low median PCR cycle threshold (Ct) value (a proxy for high virus load). This value was closely similar to 55 56 the median Ct value for unvaccinated patients with COVID-19 caused by Delta variants, 57 suggesting that fully vaccinated individuals can transmit SARS-CoV-2 to others. 58 Patients infected with Alpha and Delta variants had several significant differences. Our integrated analysis emphasizes that vaccines used in the United States are highly 59 effective in decreasing severe COVID-19 disease, hospitalizations, and deaths. 60

61

62

- 64 [Introduction]
- 65
- 66 Delta variants of concern (VOCs) of SARS-CoV-2 such as B.1.617.2, AY.3, and AY.4
- are the focus of intense international concern because they are causing widespread
- 68 COVID-19 disease in the United States, Southeast Asia, Europe, and elsewhere
- 69 (https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/variant-surveillance/variant-
- 70 <u>info.html</u>, last accessed: August 18, 2021;
- 71 <u>https://www.gov.uk/government/collections/new-sars-cov-2-variant</u>, last accessed:
- August 18, 2021)¹. For example, Delta has replaced the Alpha variant in the United
- 73 Kingdom, previously the cause of virtually all COVID-19 cases in that country
- 74 (https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---
- 75 <u>13-july-2021</u>, last accessed August 18, 2021;
- 76 <u>https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditions</u>
- 77 anddiseases/bulletins/coronaviruscovid19infectionsurveypilot/9july2021, last accessed
- August 18, 2021). Vaccine breakthrough cases caused by SARS-CoV-2 variants also
- ⁷⁹ have become of considerable public health and biomedical concern worldwide²⁻⁶. To
- 80 study Delta spread and vaccine breakthrough cases in metropolitan Houston, we
- sequenced the genomes of 12,221 SARS-CoV-2 from patient samples acquired March
- 15, 2021 through August 26, 2021 using an Illumina NovaSeq 6000 instrument and
- 83 methods described previously^{7, 8}. This period includes the time from initial identification
- of Delta-related VOCs in late April in our large Houston Methodist healthcare system
- until Delta VOCs caused the supermajority (99%) of all new cases. The sequenced

It is made available under a CC-BY-NC-ND 4.0 International license .

86	sample is 88% of the 13,839 total COVID-19 cases diagnosed in our health system
87	during the study period. We also compared characteristics of patients infected with
88	Alpha and Delta VOCs, an analysis that identified several significant differences
89	between patients infected with these two variants.
90	
91	
92	Materials and Methods
93	

94 Patient Specimens

95

96 Specimens were obtained from registered patients at Houston Methodist hospitals. associated facilities (e.g., urgent care centers), and institutions in the Houston 97 metropolitan region that use our laboratory services. The great majority of individuals 98 99 had signs or symptoms consistent with COVID-19 disease. For analyses focusing on 100 the Delta family variants, a comprehensive sample of genomes obtained from March 15, 101 2021 through August 26, 2021. This time frame was chosen because it represents the 102 period during which the downturn of our third wave was occurring, and soon after we 103 identified the first Delta variant case in our health care system. Subequently, Delta 104 variants increased rapidly to become 99.7% of all cases. The study included 12,221 105 unique patients identified in this time frame for whom we had SARS-CoV-2 genome sequences. For analyses comparing features of patients infected with the Delta variants 106

107	and Alpha VOC, a comprehensive sample of genomes obtained from January 1, 2021
108	through August 26, 2021. This time frame represents the period during which we
109	identified the first Alpha variant case in our health care system. This VOC increased
110	rapidly and peaked, and then decreased to cause less than 1% of all cases in the
111	region. This part of the study included 23,665 unique patients identified in the January
112	1, 2021 through August 26, 2021 period. The work was approved by the Houston
113	Methodist Research Institute Institutional Review Board (IRB1010-0199).
114	
115	SARS-CoV-2 Molecular Diagnostic Testing
116	
117	Specimens obtained from symptomatic patients with a suspicion for COVID-19 disease
118	were tested in the Molecular Diagnostics Laboratory at Houston Methodist Hospital
119	using assays granted Emergency Use Authorization (EUA) from the FDA
120	(https://www.fda.gov/medical-devices/emergency-situations-medical-devices/faqs-
121	diagnostic-testing-sars-cov-2#offeringtests, last accessed June 7, 2021). Multiple
122	molecular testing platforms were used, including the COVID-19 test or RP2.1 test with
123	BioFire Film Array instruments, the Xpert Xpress SARS-CoV-2 test using Cepheid
124	GeneXpert Infinity or Cepheid GeneXpert Xpress IV instruments, the cobas SARS-CoV-
125	2 & Influenza A/B Assay using the Roche Liat system, the SARS-CoV-2 Assay using
126	the Hologic Panther instrument, the Aptima SARS-CoV-2 Assay using the Hologic
127	Panther Fusion system, the Cobas SARS-CoV-2 test using the Roche 6800 system,
128	

It is made available under a CC-BY-NC-ND 4.0 International license .

129	performed on material obtained from nasopharyngeal swabs immersed in universal
130	transport media (UTM); oropharyngeal or nasal swabs, bronchoalveolar lavage fluid, or
131	sputum treated with dithiothreitol (DTT) were sometimes used. Standardized specimen
132	collection methods were used (https://vimeo.com/396996468/2228335d56, last
133	accessed June 7, 2021).
134	
135	SARS-CoV-2 Genome Sequencing
136	
137	Libraries for whole SARS-CoV-2 genome sequencing were prepared according to
138	version 3 or version 4 (https://community.artic.network/t/sars-cov-2-version-4-scheme-
139	release/312, last accessed August 19, 2021) of the ARTIC nCoV-2019 sequencing
140	protocol. We used a semi-automated workflow described previously7, 8 that employed
141	BioMek i7 liquid handling workstations (Beckman Coulter Life Sciences) and MANTIS
142	automated liquid handlers (FORMULATRIX). Short sequence reads were generated
143	with a NovaSeq 6000 instrument (Illumina). For continuity of the epidemiologic analysis
144	in the study period, we included some genome sequences reported in a recent
145	publication.8
146	
147	SARS-CoV-2 Genome Sequence Analysis and Identification of Variants
148	
149	Viral genomes were assembled with the BV-BRC SARS-Cov2 assembly service
150	(https://www.bv-brc.org/app/ComprehensiveSARS2Analysis, last accessed June 7,

151	2021, requires registration). The One Codex SARS-CoV-2 variant calling and
152	consensus assembly pipeline was used to assemble all sequences
153	(https://github.com/onecodex/sars-cov-2.git, last accessed June 7, 2021) using default
154	parameters and a minimum read depth of 3. Briefly, the pipeline uses seqtk version 1.3-
155	r116 for sequence trimming (https://github.com/lh3/seqtk.git, last accessed June 7,
156	2021); minimap version 2.1 for aligning reads against reference genome Wuhan-Hu-1
157	(NC_045512.2); samtools version 1.11 for sequence and file manipulation; and iVar
158	version 1.2.2 for primer trimming and variant calling. Genetic lineages, VOCs, and
159	variants of interest (VOIs) were identified based on genome sequence data and
160	designated by Pangolin v. 3.1.11 with pangoLEARN module 2021-08-09 (https://cov-
161	lineages.org/resources/pangolin.html, last accessed August 18, 2021).
162	There is a known problem with the ARTIC V3 primer set that results in lack of
162 163	There is a known problem with the ARTIC V3 primer set that results in lack of detection or ambiguity of the G142D and D950N single nucleotide variants, even though
163	detection or ambiguity of the G142D and D950N single nucleotide variants, even though
163 164	detection or ambiguity of the G142D and D950N single nucleotide variants, even though these amino acid changes (142D and 950N) are present in the overwhelming majority of
163 164 165	detection or ambiguity of the G142D and D950N single nucleotide variants, even though these amino acid changes (142D and 950N) are present in the overwhelming majority of B.1.617.2 Delta variant isolates (<u>https://community.artic.network/t/sars-cov-2-version-4-</u>
163 164 165 166	detection or ambiguity of the G142D and D950N single nucleotide variants, even though these amino acid changes (142D and 950N) are present in the overwhelming majority of B.1.617.2 Delta variant isolates (<u>https://community.artic.network/t/sars-cov-2-version-4-</u> <u>scheme-release/312</u> , last accessed September 1, 2021, <u>https://outbreak.info/compare-</u>
163 164 165 166 167	detection or ambiguity of the G142D and D950N single nucleotide variants, even though these amino acid changes (142D and 950N) are present in the overwhelming majority of B.1.617.2 Delta variant isolates (https://community.artic.network/t/sars-cov-2-version-4- scheme-release/312, last accessed September 1, 2021, https://outbreak.info/compare- lineages?pango=B.1.617.2&gene=S&threshold=0.2, last accessed September 1, 2021).
163 164 165 166 167 168	detection or ambiguity of the G142D and D950N single nucleotide variants, even though these amino acid changes (142D and 950N) are present in the overwhelming majority of B.1.617.2 Delta variant isolates (https://community.artic.network/t/sars-cov-2-version-4- scheme-release/312, last accessed September 1, 2021, https://outbreak.info/compare- lineages?pango=B.1.617.2&gene=S&threshold=0.2, last accessed September 1, 2021). After we transitioned to ARTIC V4, we observed that all Delta variant strain haplotypes
163 164 165 166 167 168 169	detection or ambiguity of the G142D and D950N single nucleotide variants, even though these amino acid changes (142D and 950N) are present in the overwhelming majority of B.1.617.2 Delta variant isolates (https://community.artic.network/t/sars-cov-2-version-4- scheme-release/312, last accessed September 1, 2021, https://outbreak.info/compare- lineages?pango=B.1.617.2&gene=S&threshold=0.2, last accessed September 1, 2021). After we transitioned to ARTIC V4, we observed that all Delta variant strain haplotypes contained both 142D and 950N polymorphisms except for four isolates, two of which

It is made available under a CC-BY-NC-ND 4.0 International license .

173

174 Patient Metadata and Geospatial Analysis

- 175
- 176 Patient metadata (**Table 1**, **Table 2**, **Table 3**) were acquired from the electronic medical
- 177 record by standard informatics methods. Patient home address zip codes were used to
- visualize the geospatial distribution of spread for each VOC and VOI. Figures were
- 179 generated with Tableau version 2020.3.4 (Tableau Software, LLC, Seattle, WA). A
- 180 vaccination breakthrough case was defined as a PCR-positive sample from a patient
- obtained greater than 14 days after full vaccination (i.e., both doses of the Pfizer or
- 182 Moderna mRNA vaccines) was completed. For some cases, manual chart review was

183 conducted to resolve discrepancies or ambiguities.

184

185

186 **Results**

187

188 Delta Epidemiologic Wave

189

190 The first Houston Methodist patient infected with a Delta family variant was identified in

- 191 mid-April, 2021, a time when the Alpha VOC was responsible for most COVID-19 cases
- in metropolitan Houston, and the area was experiencing a steady downturn in total
- 193 number of new COVID-19 cases (Figure 1). Delta VOCs slowly increased in frequency,

194	but beginning in early July a sharp uptick of COVID-19 cases caused by these VOCs
195	occurred (Figure 1, Figure 2), with an estimated doubling time of approximately seven
196	days. By late August, the genome data showed that Delta VOCs accounted for 99.7% of
197	all new COVID-19 cases in our health system (Figure 2). This represents the fourth
198	wave of COVID-19 cases in metropolitan Houston (Figure 1).
199	During the study period 13,839 COVID-19 cases were diagnosed in our
200	healthcare system, and we sequenced 12,221 SARS-CoV-2 genomes, representing
201	88% of cases. We identified 8,297 patients (67.9% of the total sequenced) with Delta
202	VOCs (Table 1A). The majority (62%; 2,443 of 3,924) of the non-Delta COVID-19 cases
203	occurring during the study period were caused by the Alpha (UK B.1.1.7) VOC.
204	Consistent with extensive infections caused by Delta variants in Southeast Asia
205	and elsewhere (https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/variant-
206	surveillance/variant-info.html, last accessed: August 18, 2021;
207	https://www.gov.uk/government/collections/new-sars-cov-2-variant, last accessed:
208	August 18, 2021) ¹ , several patients had very recent travel histories to countries with a
209	high prevalence of these VOCs, suggesting acquisition abroad and importation into
210	Houston. Fifty-five patients with Delta Plus (Delta plus the K417N spike amino acid
211	Tiousion. Titty-tive patients with Delta Tius (Delta plus the R41714 spike attitto acid
211	substitution) were identified.
212	
	substitution) were identified.
212	substitution) were identified. To understand the geospatial distribution of Delta in metropolitan Houston, we
212 213	substitution) were identified. To understand the geospatial distribution of Delta in metropolitan Houston, we acquired patient metadata from the electronic medical record by standard informatics

It is made available under a CC-BY-NC-ND 4.0 International license .

216	zip codes represented (Figure 2), indicative of the ability of Delta variants to spread
217	very effectively and rapidly between individuals. Analysis of Delta VOCs dissemination
218	over time illustrated the rapid spread of these variants throughout the Houston
219	metroplex (Figure 2).
220	
221	Delta Family Subvariants
222	
223	A total of 893 subvariants was identified based on amino acid changes in spike protein.
224	The six most common identified in our study are shown (Figure 3) and these
225	represented 74% of the 8,297 Delta samples. We believe the unexpectedly high number
226	of subvariants may reflect several contributing factors, including the large population
227	sizes and genetic diversity of Delta globally, and multiple independent introductions into
228	the Houston area. Other potential contributors include high virus load in patients on
229	initial diagnosis (Table 1), infection of partially immunized hosts, and prolonged
230	infections occurring in relatively immunocompromised individuals ⁹⁻¹² . In this regard,
231	some of our patients had a history of cancer and organ transplants (data not shown).
232	Patients infected with the same subvariant usually lived in different zip codes and
233	generally had no apparent epidemiological link, consistent with the ability of Delta to
234	spread very rapidly. In some cases there were clear epidemiologic links between
235	patients infected with the same subvariant, including being members of the same
236	household.

It is made available under a CC-BY-NC-ND 4.0 International license .

- There is a considerable lack of detailed information about patients in the United
 States with COVID-19 caused by Delta VOCs
- 239 (https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---
- 240 <u>13-july-2021</u>, last accessed August 18, 2021). Compared to all other patients in the time
- frame studied, there was no significant difference in gender or median age (**Table 1**).
- 242 However, Delta variant patients were admitted significantly less frequently than other
- 243 patients and had a significantly longer median hospital length of stay, but there was no
- significant difference in mortality rate (**Table 1**). Delta cases were more likely to be
- Asian (consistent with multiple recent entry points from abroad) and Caucasian and less
- 246 likely to be Hispanic or Latino, have significantly lower PCR cycle threshold (Ct) values
- 247 (a proxy for higher virus load, a finding consistent with increased transmissibility of Delta
- variants) on initial diagnosis, and cause a significantly higher rate of vaccine
- breakthrough cases (23.4% compared to 6.2% for all other variants combined) (Table
- 1). Consistent with Delta causing an increased number of vaccine breakthrough cases,
- it has been reported that this variant has reduced sensitivity to antibody neutralization *in*
- 252 *vitro*¹³.
- 253

254 Comparison of Delta and Alpha COVID-19 Cases

255

The occurrence of a prominent third wave of COVID-19 cases in Houston caused by the Alpha VOC (**Figure 1**) provided the opportunity of compare and contrast large disease waves caused by two genetically distinct SARS-CoV-2 genotypes. For this analysis we

It is made available under a CC-BY-NC-ND 4.0 International license .

259	included Alpha VOC cases beginning January 1, 2021, because that time was soon
260	after our first recorded Houston Methodist case caused by this variant. The number of
261	Delta cases studied (n = 8,297) was much greater than the number of Alpha cases (n = $(n + 1)$
262	3,262) (Table 2). The two patient populations differed significantly in many
263	characteristics, including median age, ethnicity, median PCR Ct level, admission rates,
264	maximum respiratory support, rate of vaccine breakthrough, median length of stay, and
265	mortality (Table 2).
266	
267	Vaccine Breakthrough Cases
268	
269	We next analyzed vaccine breakthrough cases (Table 3). We found 2,187 of the 12,221
270	total patients (17.9%) for whom we have genome sequence data met the CDC definition

of vaccine breakthrough cases (**Table 1 and Table 3**). There was no simple relationship

between the time elapsed since administration of the second (booster) vaccination and

the date of vaccination breakthrough (data not shown). These 2,187 patients received

272

either the Pfizer-BioNTech BNT162b2 (n = 1,875, 86%), Moderna mRNA-1273 (n =

275 232, 11%), or J&J/Janssen JNJ-78436735 (*n* = 74, 3%) vaccine; vaccine type was not

276 specified for six individuals. This distribution generally reflects the great majority of

277 BNT162b2 vaccination doses given in our health system and should not be interpreted

- to mean that the Pfizer-BioNTech and Moderna products are unusually prone to
- breakthrough cases, as these mRNA vaccines are highly efficacious^{6, 14-20}. Vaccinated
- 280 patients infected with non-Delta variants had a significantly higher Ct value on initial

It is made available under a CC-BY-NC-ND 4.0 International license .

diagnosis, likely indicating better vaccine protection, lower virus load, and decreased
probability of transmission. Compared to all other variants combined, a significantly
lower percentage (25.7% compared to 36.8%; *P*<0.0004) of patients with breakthrough
cases caused by Delta variants was admitted to the hospital (**Table 1 and Table 3**).
Lambda and Mu Variants of Interest

288 The Lambda variant of interest was first reported in November, 2020. It has very 289 recently attracted widespread media and public interest because it has caused large 290 numbers of infections in Peru and Ecuador, and has been reported to cause COVID-19 291 in the U.S^{21, 22} (https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/, last accessed September 2, 2021). There has been speculation that Lambda may become 292 293 numerically prominent in the United States and other countries, in part because its spike 294 protein differs immunologically and has been reported to be partially resistant in vitro to vaccine-induced sera and therapeutic monoclonal antibodies²³⁻²⁵. Because of this 295 296 concern, we inspected our large genome sequence database to determine if Lambda 297 was present, and if so, had it increased substantially in the Houston metropolitan region. The analysis identified only eight cases caused by this variant of interest, the first one 298 299 identified in our Houston Methodist patient population in mid-July, 2021 (Figure 4A). These patients lived in several non-contiguous zip codes throughout the metroplex, that 300 301 is, were not restricted to a single geographic area of greater Houston (Figure 4A, B).

It is made available under a CC-BY-NC-ND 4.0 International license .

302	The Mu VOI was initially identified in Colombia in January, 2021, and has been
303	reported to now account for 39% of cases in that country ²⁶ . Mu also has been found in
304	many other countries worldwide, and recently it was reported that the Mu variant has
305	increased resistance in vitro to antibodies elicited by vaccination with BNT162b2 and
306	natural infection by SARS-CoV-2 ²⁷ . We identified 52 cases of COVID-19 caused by the
307	Mu VOI, and similar to the Lambda these cases were distributed in multiple areas in the
308	Houston metropolitan region (Figure 4C, D).

309

310

311 **Discussion**

312

313 In this work, we analyzed SARS-CoV-2 Delta VOCs population genomics and patient characteristics for 12,221 patients, focusing on mid-March, 2021 through late August, 314 315 2021, a time frame in which there was essentially total replacement of the previously 316 dominant Alpha (B.1.1.7) VOC by Delta family VOCs. During this five-month period, a 317 substantial increase in COVID-19 cases occurred in our healthcare system and 318 throughout all of the Houston metropolitan area, virtually all driven by rapid 319 dissemination of the highly contagious Delta family variants. The study was based 320 predominantly on genome sequence analysis of 12,221 SARS-CoV-2 samples from 321 socioeconomically, geographically, and ethnically diverse patients. Several key findings 322 were made, including (i) Delta family VOCs supplanted the Alpha VOC in a relatively

It is made available under a CC-BY-NC-ND 4.0 International license .

323	short period of time, (ii) regardless of vaccination status, on initial diagnosis, compared
324	to patients infected by other VOCs, patients infected by Delta VOCs had significantly
325	lower Ct values, likely indicating significantly higher viral load in the nasopharynx, (iii)
326	Delta caused significantly more vaccine breakthrough cases than other VOCs, (iv)
327	significantly fewer fully vaccinated individuals required hospitalization, (v) the Lambda
328	and Mu VOIs were identified but were rare, and they did not increase to substantial
329	levels in the time frame studied.
330	Our genome sequence data document a rapid increase of Delta variant cases in
331	metropolitan Houston and a considerable corresponding decrease of COVID-19 cases
332	caused by Alpha and other variants, findings similar to epidemiologic trends observed in
333	the UK (https://www.who.int/publications/m/item/weekly-epidemiological-update-on-
334	covid-1913-july-2021, last accessed August 18, 2021;
335	https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditions
336	anddiseases/bulletins/coronaviruscovid19infectionsurveypilot/9july2021, last accessed
337	August 18, 2021). In less than four months, Delta VOCs increased from an initial
338	documented case in our large patient population to cause 99.7% of all cases in our
339	healthcare system. The rapid increase in Delta cases we documented is responsible for
340	a prominent fourth wave of COVID-19 disease in Houston that is ongoing (Figure 1).
341	Our findings are consistent with Delta VOCs epidemiologic data reported from other
342	regions of the US.

We found that Delta was significantly more likely to cause vaccine breakthrough cases (**Table 1 and Table 3**). However, importantly, 17.9% of all of our 12,221 COVID-

It is made available under a CC-BY-NC-ND 4.0 International license .

345	19 cases with genome sequence data occurred in fully vaccinated individuals, but only
346	589 (4.8%) of these patients required hospitalization. Vaccine breakthrough cases have
347	emerged as an area of great interest, especially so with the increasing percentage of
348	COVID-19 cases caused by Delta variants and the recognition that they are important
349	causes of breakthroughs ²⁸⁻³³ . Although our analysis did not identify a simple relationship
350	between the time elapsed since administration of the second booster vaccination and
351	the date of vaccination breakthrough, this is an important area for continued study.
352	Similarly, we did not study the potential relationship between vaccination breakthrough
353	and waning immunity, but studies of this topic are ongoing.
354	Some investigators have speculated that the Lambda and Mu variants may
355	become a major concern in future surges. Although in principle this is possible, our data
356	show that neither variant has increased substantially in our metropolitan area during the
357	time frame studied. Thus, our genome analysis of a large set of samples from the first
358	eight months of 2021 does not currently support this speculation, although
359	circumstances may change in the future. Because we are sequencing the genome of
360	the great majority of SARS-CoV-2 causing COVID-19 in our diverse patient population,
361	we are continuously monitoring the growth trajectory of these and other variants in a
362	major metropolitan region in the US. Thus, our ongoing near-real-time sequencing of
363	SARS-CoV-2 genomes responsible for COVID-19 cases in metropolitan Houston
364	provides a facile strategy to assess changes in the virus population composition and
365	molecular evolution in this populous area.

It is made available under a CC-BY-NC-ND 4.0 International license .

366	In the aggregate, our data add critical new information to the finding that these
367	three vaccines are highly efficacious in decreasing severe COVID-19 disease,
368	hospitalizations, and deaths ^{6, 17, 20} . Further, the present study highlights the importance
369	of analyzing SARS-CoV-2 genome data integrated with linked patient metadata and
370	stresses the need to continue to do this in near-real time as the pandemic continues,
371	the virus evolves, and new variants with potentially increased fitness are generated.
372	Analyses of this type are also important in the context of vaccine formulation and long
373	COVID, an increasing health and economic problem globally.
374	

375

376 Acknowledgments

377

378 We thank Drs. Marc Boom and Dirk Sostman for their ongoing support and Dr. Sasha 379 Pejerrey for editorial contributions and Dr. Heather McConnell for help with figures. The 380 research was supported by the Houston Methodist Academic Institute Infectious 381 Diseases Fund and many generous Houston philanthropists. James J. Davis was 382 funded in whole or in part with Federal funds from the National Institute of Allergy and 383 Infectious Diseases, National Institutes of Health, Department of Health and Human 384 Services, under Contract No. 75N93019C00076. The funders had no role in the design 385 and conduct of the study; collection, management, analysis, and interpretation of the 386 data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. 387

It is made available under a CC-BY-NC-ND 4.0 International license .

- 388 The findings and conclusions in this article are those of the authors and do not
- necessarily reflect the views of the U.S. Army.
- 390 We declare that we have no conflict of interest.
- 391
- 392

393 Author Contributions

395	P.A.C., R.J.O.,	S.W.L., \$	S.S.,	and J.M.M.	had full	access t	to all	l study	data	and take	е
-----	-----------------	------------	-------	------------	----------	----------	--------	---------	------	----------	---

- responsibility for the integrity of the data and the accuracy of the data analysis; concept
- and design by J.M.M., P.A.C., R.J.O., and S.W.L; data acquisition, analysis, or
- interpretation by all authors; drafting of the manuscript by all authors; statistical analysis
- by P.A.C.; funding obtained by J.M.M. and J.J.D.; overall supervision by J.M.M; P.A.C.,
- 400 R.J.O., and S.W.L. contributed equally and are co-first authors.
- 401
- 402
- 403 Institutional Review Board statement: This work was approved by the Houston
- 404 Methodist Research institutional review board (IRB1010-0199).
- 405
- 406
- 407 Additional Information: Genome data used in this study have been deposited to408 GISAID.
- 409

It is made available under a CC-BY-NC-ND 4.0 International license .

410 Figure Legends

411

412	Figure 1 Epidemiologic curve showing four COVID-19 disease waves in Houston
413	Methodist patients. Number of new COVID-19 cases (y-axis) totals are shown as a +/-
414	three-day moving average. Each of the four waves is shown in a different color simply
415	as a stylistic device. The first and second waves were composed of a heterogenous
416	array of SARS-CoV-2 genotypes. The Alpha variant shown in the third wave and the
417	Delta variant shown in the fourth indicate their numeric prominence in those waves, and
418	should not be interpreted to mean that all cases in the third and fourth waves were
419	caused by Alpha and Delta VOCs, respectively. The figure was generated with Tableau
420	version 2020.3.4 (Tableau Software, LLC, Seattle, WA). The curve mirrors that of
421	disease activity in metropolitan Houston, Texas.
422	
422 423	Figure 2 Increase in Delta frequency over time and distribution in metropolitan
	Figure 2 Increase in Delta frequency over time and distribution in metropolitan Houston. The study time frame was March 15, 2021 through August 26, 2021. A:
423	
423 424	Houston. The study time frame was March 15, 2021 through August 26, 2021. A:
423 424 425	Houston. The study time frame was March 15, 2021 through August 26, 2021. A: Cumulative increase in Delta during the study period; y-axis is the cumulative number of
423 424 425 426	Houston. The study time frame was March 15, 2021 through August 26, 2021. A: Cumulative increase in Delta during the study period; y-axis is the cumulative number of new COVID-19 cases. At the end of the study period, Delta caused 99.7% of all COVID-
423 424 425 426 427	Houston. The study time frame was March 15, 2021 through August 26, 2021. A : Cumulative increase in Delta during the study period; y-axis is the cumulative number of new COVID-19 cases. At the end of the study period, Delta caused 99.7% of all COVID- 19 cases. B – E : Geospatial distribution of Delta based on home address zip code for
423 424 425 426 427 428	Houston. The study time frame was March 15, 2021 through August 26, 2021. A : Cumulative increase in Delta during the study period; y-axis is the cumulative number of new COVID-19 cases. At the end of the study period, Delta caused 99.7% of all COVID- 19 cases. B – E : Geospatial distribution of Delta based on home address zip code for each patient. B : April 15 – May 15; C : April 15 – June 15; D : April 15 – July 15; E : April

It is made available under a CC-BY-NC-ND 4.0 International license .

432	Figure 3 Structural changes present in spike protein of the six most abundant Delta
433	subvariants identified in the study. The numbers denote the number of patients with
434	each subvariant identified in this study. These six subvariants represented 74% of the
435	8,297 Delta samples in our study. S1-NTD, S1 domain-aminoterminal domain; S1-RBD,
436	S1 domain-receptor binding domain; S1, S1 domain; S2, S2 domain. The figure is a
437	modified version of one published previously ⁸ .
438	
439	Figure 4 Lambda and Mu variants identified in metropolitan Houston in our patient
440	population. A: cumulative increase in the cases caused by Lambda variants identified in
441	the study; B: geospatial distribution of these Lambda variants based on the home
442	address zip code for each patient. C: cumulative increase in cases caused by the Mu

443 variants identified in the study; **D**: geospatial distribution of the Mu variants based on

the home address zip code for each patient. Figures were generated using Tableau

445 version 2020.3.4. (Tableau Software, LLC, Seattle, WA).

446

It is made available under a CC-BY-NC-ND 4.0 International license .

448 **References**

- 450 [1] Dhar MS, Marwal R, Radhakrishnan V, Ponnusamy K, Jolly B, Bhoyar RC, Fatihi S, Datta M,
- 451 Singh P, Sharma U, Ujjainia R, Naushin S, Bhateja N, Divakar MK, Sardana V, Singh MK, Imran M,
- 452 Senthivel V, Maurya R, Jha N, Mehta P, Rophina M, Arvinden V, Chaudhary U, Thukral L, Pandey
- 453 R, Dash D, Faruq M, Lall H, Gogia H, Madan P, Kulkarni S, Chauhan H, Sengupta S, Kabra S,
- 454 Consortium TIS-C-G, Singh SK, Agrawal A, Rakshit P: Genomic characterization and
- 455 Epidemiology of an emerging SARS-CoV-2 variant in Delhi, India. medRxiv
- 456 2021:2021.06.02.21258076.
- 457 [2] Hacisuleyman E, Hale C, Saito Y, Blachere NE, Bergh M, Conlon EG, Schaefer-Babajew DJ,
- 458 DaSilva J, Muecksch F, Gaebler C, Lifton R, Nussenzweig MC, Hatziioannou T, Bieniasz PD,
- 459 Darnell RB: Vaccine Breakthrough Infections with SARS-CoV-2 Variants. N Engl J Med 2021,
- 460 384:2212-8.
- 461 [3] Brosh-Nissimov T, Orenbuch-Harroch E, Chowers M, Elbaz M, Nesher L, Stein M, Maor Y,
- 462 Cohen R, Hussein K, Weinberger M, Zimhony O, Chazan B, Najjar R, Zayyad H, Rahav G, Wiener-
- 463 Well Y: BNT162b2 vaccine breakthrough: clinical characteristics of 152 fully-vaccinated
- 464 hospitalized COVID-19 patients in Israel. Clin Microbiol Infect 2021.
- 465 [4] COVID-19 Vaccine Breakthrough Infections Reported to CDC United States, January 1-April
- 466 30, 2021. MMWR Morb Mortal Wkly Rep 2021, 70:792-3.
- 467 [5] Kustin T, Harel N, Finkel U, Perchik S, Harari S, Tahor M, Caspi I, Levy R, Leshchinsky M, Ken
- 468 Dror S, Bergerzon G, Gadban H, Gadban F, Eliassian E, Shimron O, Saleh L, Ben-Zvi H, Keren
- 469 Taraday E, Amichay D, Ben-Dor A, Sagas D, Strauss M, Shemer Avni Y, Huppert A, Kepten E,
- 470 Balicer RD, Netzer D, Ben-Shachar S, Stern A: Evidence for increased breakthrough rates of
- 471 SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals. Nat Med 2021.
- 472 [6] Tenforde MW, Patel MM, Ginde AA, Douin DJ, Talbot HK, Casey JD, Mohr NM, Zepeski A,
- 473 Gaglani M, McNeal T, Ghamande S, Shapiro NI, Gibbs KW, Files DC, Hager DN, Shehu A, Prekker
- 474 ME, Erickson HL, Exline MC, Gong MN, Mohamed A, Henning DJ, Peltan ID, Brown SM, Martin
- 475 ET, Monto AS, Khan A, Hough CT, Busse L, Ten Lohuis CC, Duggal A, Wilson JG, Gordon AJ, Qadir
- 476 N, Chang SY, Mallow C, Gershengorn HB, Babcock HM, Kwon JH, Halasa N, Chappell JD, Lauring
- 477 AS, Grijalva CG, Rice TW, Jones ID, Stubblefield WB, Baughman A, Womack KN, Lindsell CJ, Hart
- 478 KW, Zhu Y, Olson SM, Stephenson M, Schrag SJ, Kobayashi M, Verani JR, Self WH: Effectiveness
- 479 of SARS-CoV-2 mRNA Vaccines for Preventing Covid-19 Hospitalizations in the United States.
- 480 Clin Infect Dis 2021.
- 481 [7] Long SW, Olsen RJ, Christensen PA, Subedi S, Olson R, Davis JJ, Saavedra MO, Yerramilli P,
- 482 Pruitt L, Reppond K, Shyer MN, Cambric J, Finkelstein IJ, Gollihar J, Musser JM: Sequence
- 483 Analysis of 20,453 Severe Acute Respiratory Syndrome Coronavirus 2 Genomes from the
- 484 Houston Metropolitan Area Identifies the Emergence and Widespread Distribution of Multiple
- 485 Isolates of All Major Variants of Concern. Am J Pathol 2021, 191:983-92.
- 486 [8] Olsen RJ, Christensen PA, Long SW, Subedi S, Hodjat P, Olson R, Nguyen M, Davis JJ,
- 487 Yerramilli P, Saavedra MO, Pruitt L, Reppond K, Shyer MN, Cambric J, Gadd R, Thakur RM,
- 488 Batajoo A, Finkelstein IJ, Gollihar J, Musser JM: Trajectory of Growth of Severe Acute

- 489 Respiratory (SARS-CoV-2) Syndrome Coronavirus 2 Variants in Houston, Texas, January through
 490 May 2021, Based on 12,476 Genome Sequences. Am J Pathol 2021.
- 491 [9] Clark SA, Clark LE, Pan J, Coscia A, McKay LGA, Shankar S, Johnson RI, Brusic V, Choudhary
- 492 MC, Regan J, Li JZ, Griffiths A, Abraham J: SARS-CoV-2 evolution in an immunocompromised
- 493 host reveals shared neutralization escape mechanisms. Cell 2021, 184:2605-17.e18.
- 494 [10] Choi B, Choudhary MC, Regan J, Sparks JA, Padera RF, Qiu X, Solomon IH, Kuo HH, Boucau J,
- 495 Bowman K, Adhikari UD, Winkler ML, Mueller AA, Hsu TY, Desjardins M, Baden LR, Chan BT,
- 496 Walker BD, Lichterfeld M, Brigl M, Kwon DS, Kanjilal S, Richardson ET, Jonsson AH, Alter G,
- 497 Barczak AK, Hanage WP, Yu XG, Gaiha GD, Seaman MS, Cernadas M, Li JZ: Persistence and
- 498 Evolution of SARS-CoV-2 in an Immunocompromised Host. N Engl J Med 2020, 383:2291-3.
- 499 [11] Baang JH, Smith C, Mirabelli C, Valesano AL, Manthei DM, Bachman MA, Wobus CE, Adams
- 500 M, Washer L, Martin ET, Lauring AS: Prolonged Severe Acute Respiratory Syndrome Coronavirus
- 501 2 Replication in an Immunocompromised Patient. J Infect Dis 2021, 223:23-7.
- 502 [12] Hensley MK, Bain WG, Jacobs J, Nambulli S, Parikh U, Cillo A, Staines B, Heaps A,
- 503 Sobolewski MD, Rennick LJ, Macatangay BJC, Klamar-Blain C, Kitsios GD, Methé B,
- 504 Somasundaram A, Bruno TC, Cardello C, Shan F, Workman C, Ray P, Ray A, Lee J, Sethi R,
- 505 Schwarzmann WE, Ladinsky MS, Bjorkman PJ, Vignali DA, Duprex WP, Agha ME, Mellors JW,
- 506 McCormick KD, Morris A, Haidar G: Intractable Coronavirus Disease 2019 (COVID-19) and
- 507 Prolonged Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Replication in a
- 508 Chimeric Antigen Receptor-Modified T-Cell Therapy Recipient: A Case Study. Clinical Infectious509 Diseases 2021.
- 510 [13] Planas D, Veyer D, Baidaliuk A, Staropoli I, Guivel-Benhassine F, Rajah MM, Planchais C,
- 511 Porrot F, Robillard N, Puech J, Prot M, Gallais F, Gantner P, Velay A, Le Guen J, Kassis-Chikhani
- 512 N, Edriss D, Belec L, Seve A, Courtellemont L, Péré H, Hocqueloux L, Fafi-Kremer S, Prazuck T,
- 513 Mouquet H, Bruel T, Simon-Lorière E, Rey FA, Schwartz O: Reduced sensitivity of SARS-CoV-2
- 514 variant Delta to antibody neutralization. Nature 2021.
- 515 [14] Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Pérez Marc G,
- 516 Moreira ED, Zerbini C, Bailey R, Swanson KA, Roychoudhury S, Koury K, Li P, Kalina WV, Cooper
- 517 D, Frenck RW, Hammitt LL, Türeci Ö, Nell H, Schaefer A, Ünal S, Tresnan DB, Mather S,
- 518 Dormitzer PR, Şahin U, Jansen KU, Gruber WC: Safety and Efficacy of the BNT162b2 mRNA
- 519 Covid-19 Vaccine. New England Journal of Medicine 2020, 383:2603-15.
- 520 [15] Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, Diemert D, Spector SA,
- 521 Rouphael N, Creech CB, McGettigan J, Khetan S, Segall N, Solis J, Brosz A, Fierro C, Schwartz H,
- 522 Neuzil K, Corey L, Gilbert P, Janes H, Follmann D, Marovich M, Mascola J, Polakowski L,
- 523 Ledgerwood J, Graham BS, Bennett H, Pajon R, Knightly C, Leav B, Deng W, Zhou H, Han S,
- 524 Ivarsson M, Miller J, Zaks T: Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. New
- 525 England Journal of Medicine 2020, 384:403-16.
- 526 [16] Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, Angus B, Baillie VL,
- 527 Barnabas SL, Bhorat QE, Bibi S, Briner C, Cicconi P, Collins AM, Colin-Jones R, Cutland CL, Darton
- 528 TC, Dheda K, Duncan CJA, Emary KRW, Ewer KJ, Fairlie L, Faust SN, Feng S, Ferreira DM, Finn A,
- 529 Goodman AL, Green CM, Green CA, Heath PT, Hill C, Hill H, Hirsch I, Hodgson SHC, Izu A, Jackson
- 530 S, Jenkin D, Joe CCD, Kerridge S, Koen A, Kwatra G, Lazarus R, Lawrie AM, Lelliott A, Libri V, Lillie
- 531 PJ, Mallory R, Mendes AVA, Milan EP, Minassian AM, McGregor A, Morrison H, Mujadidi YF,
- 532 Nana A, O'Reilly PJ, Padayachee SD, Pittella A, Plested E, Pollock KM, Ramasamy MN, Rhead S,

- 533 Schwarzbold AV, Singh N, Smith A, Song R, Snape MD, Sprinz E, Sutherland RK, Tarrant R,
- 534 Thomson EC, Török ME, Toshner M, Turner DPJ, Vekemans J, Villafana TL, Watson MEE,
- 535 Williams CJ, Douglas AD, Hill AVS, Lambe T, Gilbert SC, Pollard AJ: Safety and efficacy of the
- 536 ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four
- randomised controlled trials in Brazil, South Africa, and the UK. Lancet 2021, 397:99-111.
- 538 [17] Lopez Bernal J, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S, Stowe J, Tessier E,
- 539 Groves N, Dabrera G, Myers R, Campbell CNJ, Amirthalingam G, Edmunds M, Zambon M, Brown
- 540 KE, Hopkins S, Chand M, Ramsay M: Effectiveness of Covid-19 Vaccines against the B.1.617.2
- 541 (Delta) Variant. New England Journal of Medicine 2021.
- 542 [18] Abu-Raddad LJ, Chemaitelly H, Butt AA: Effectiveness of the BNT162b2 Covid-19 Vaccine
- 543 against the B.1.1.7 and B.1.351 Variants. New England Journal of Medicine 2021, 385:187-9.
- 544 [19] Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz MA, Hernán MA, Lipsitch M, Reis B,
- 545 Balicer RD: BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting. New
- 546 England Journal of Medicine 2021, 384:1412-23.
- 547 [20] Jagadeesh Kumar V, Sowpati DT, Munigela A, Banu S, Siva AB, Sasikala M, Nutalapati C,
- 548 Kulkarni A, Mukherjee P, Zaveri L, Team CC-, Team AHC-Vs, Tallapaka KB, Reddy DN: Clinical
- outcomes in vaccinated individuals hospitalized with Delta variant of SARS-CoV-2. medRxiv2021:2021.07.13.21260417.
- 551 [21] Padilla-Rojas C, Jimenez-Vasquez V, Hurtado V, Mestanza O, Molina IS, Barcena L, Morales
- 552 Ruiz S, Acedo S, Lizarraga W, Bailon H, Cáceres O, Galarza M, Rojas-Serrano N, Vargas-Herrera
- 553 N, Lope-Pari P, Huayra J, Solari L: Genomic analysis reveals a rapid spread and predominance of
- lambda (C.37) SARS-COV-2 lineage in Peru despite circulation of variants of concern. J Med Virol2021.
- 556 [22] Romero PE, Dávila-Barclay A, Salvatierra G, González L, Cuicapuza D, Solis L, Marcos-
- 557 Carbajal P, Huancachoque J, Maturrano L, Tsukayama P: The Emergence of SARS-CoV-2 Variant 558 Lambda (C.37) in South America. medRxiv 2021:2021.06.26.21259487.
- 559 [23] Tada T, Zhou H, Dcosta BM, Samanovic MI, Mulligan MJ, Landau NR: The Spike Proteins of
- 560 SARS-CoV-2 B.1.617 and B.1.618 Variants Identified in India Provide Partial Resistance to
- 561 Vaccine-elicited and Therapeutic Monoclonal Antibodies. bioRxiv 2021:2021.05.14.444076.
- 562 [24] Kimura I, Kosugi Y, Wu J, Yamasoba D, Butlertanaka EP, Tanaka YL, Liu Y, Shirakawa K,
- 563 Kazuma Y, Nomura R, Horisawa Y, Tokunaga K, Takaori-Kondo A, Arase H, Consortium TGtPJ,
- 564 Saito A, Nakagawa S, Sato K: SARS-CoV-2 Lambda variant exhibits higher infectivity and immune
- 565 resistance. bioRxiv 2021:2021.07.28.454085.
- 566 [25] Liu H, Wei P, Zhang Q, Aviszus K, Linderberger J, Yang J, Liu J, Chen Z, Waheed H, Reynoso
- 567 L, Downey GP, Frankel SK, Kappler J, Marrack P, Zhang G: The Lambda variant of SARS-CoV-2
- has a better chance than the Delta variant to escape vaccines. bioRxiv 2021:2021.08.25.457692.
- 569 [26] Laiton-Donato K, Franco-Muñoz C, Álvarez-Díaz DA, Ruiz-Moreno HA, Usme-Ciro JA, Andrés
- 570 Prada D, Reales-González J, Corchuelo S, Herrera-Sepúlveda MT, Naizaque J, Santamaría G,
- 571 Rivera J, Rojas P, Hernández Ortiz J, Cardona A, Malo D, Prieto-Alvarado F, Gómez FR, Wiesner
- 572 M, Ospina Martínez ML, Mercado-Reyes M: Characterization of the emerging B.1.621 variant of
- 573 interest of SARS-CoV-2. medRxiv 2021:2021.05.08.21256619.
- 574 [27] Uriu K, Kimura I, Shirakawa K, Takaori-Kondo A, Nakada T-a, Kaneda A, Consortium TGtPJ,
- 575 Nakagawa S, Sato K: Ineffective neutralization of the SARS-CoV-2 Mu variant by convalescent
- 576 and vaccine sera. bioRxiv 2021:2021.09.06.459005.

It is made available under a CC-BY-NC-ND 4.0 International license .

- 577 [28] Brown CM, Vostok J, Johnson H, Burns M, Gharpure R, Sami S, Sabo RT, Hall N, Foreman A,
- 578 Schubert PL, Gallagher GR, Fink T, Madoff LC, Gabriel SB, MacInnis B, Park DJ, Siddle KJ, Harik V,
- 579 Arvidson D, Brock-Fisher T, Dunn M, Kearns A, Laney AS: Outbreak of SARS-CoV-2 Infections,
- 580 Including COVID-19 Vaccine Breakthrough Infections, Associated with Large Public Gatherings -
- 581 Barnstable County, Massachusetts, July 2021. MMWR Morb Mortal Wkly Rep 2021, 70:1059-62.
- [29] Chia PY, Xiang Ong SW, Chiew CJ, Ang LW, Chavatte J-M, Mak T-M, Cui L, Kalimuddin S,
- 583 Chia WN, Tan CW, Ann Chai LY, Tan SY, Zheng S, Pin Lin RT, Wang L, Leo Y-S, Lee VJ, Lye DC,
- 584 Young BE: Virological and serological kinetics of SARS-CoV-2 Delta variant vaccine-breakthrough
- 585 infections: a multi-center cohort study. medRxiv 2021:2021.07.28.21261295.
- 586 [30] Sheikh A, McMenamin J, Taylor B, Robertson C: SARS-CoV-2 Delta VOC in Scotland:
- 587 demographics, risk of hospital admission, and vaccine effectiveness. Lancet 2021, 397:2461-2.
- 588 [31] Riemersma KK, Grogan BE, Kita-Yarbro A, Halfmann PJ, Segaloff HE, Kocharian A, Florek KR,
- 589 Westergaard R, Bateman A, Jeppson GE, Kawaoka Y, O'Connor DH, Friedrich TC, Grande KM:
- 590 Shedding of Infectious SARS-CoV-2 Despite Vaccination. medRxiv 2021:2021.07.31.21261387.
- [32] Bergwerk M, Gonen T, Lustig Y, Amit S, Lipsitch M, Cohen C, Mandelboim M, Gal Levin E,
- 592 Rubin C, Indenbaum V, Tal I, Zavitan M, Zuckerman N, Bar-Chaim A, Kreiss Y, Regev-Yochay G:
- 593 Covid-19 Breakthrough Infections in Vaccinated Health Care Workers. New England Journal of
- 594 Medicine 2021.
- 595 [33] Goldberg Y, Mandel M, Bar-On YM, Bodenheimer O, Freedman L, Haas EJ, Milo R, Alroy-
- 596 Preis S, Ash N, Huppert A: Waning immunity of the BNT162b2 vaccine: A nationwide study from 597 Israel. medRxiv 2021:2021.08.24.21262423.
- 598

It is made available under a CC-BY-NC-ND 4.0 International license .

Table 1. Summary of pertinent patient metadata for the 12,221 unique patients

	Delta Variant	Other Variants	Total	Statistical Analysis
No. (%) with data	8297 (67.9%)	3924 (32.1%)	12221	
Patient Characteristics		<u> </u>		<u> </u>
Median Age (Years)	47.3	47.9	47.5	<i>P</i> =0.1980
				Mann-Whitney
Female	4390 (52.9%)	2033 (51.8%)	6423 (52.6%)	<i>P</i> =0.2605
Male	3907 (47.1%)	1891 (48.2%)	5798 (47.4%)	Fisher's exact test
Ethnicity				
Caucasian	3648 (44.1%)	1532 (39.3%)	5180 (42.6%)	<i>P</i> <0.0001
Hispanic or Latino	2092 (25.3%)	1199 (30.8%)	3291 (27.1%)	Chi-square
Black	1877 (22.7%)	913 (23.4%)	2790 (22.9%)	
Asian	311 (3.8%)	114 (2.9%)	425 (3.5%)	
Native American	14 (0.2%)	15 (0.4%)	29 (0.2%)	
Hawaiian/Pacific Islander	20 (0.2%)	5 (0.1%)	25 (0.2%)	
Unavailable	303 (3.7%)	119 (3.1%)	422 (3.5%)	
BMI				
Median BMI	29.7	30.3	30.0	<i>P</i> <0.0001
				Mann-Whitney
Admission Data	I	I	I	L
Admitted	3321 (40.0%)	2120 (54.0%)	5441 (44.5%)	<i>P</i> <0.0001
Not Admitted	4976 (60.0%)	1804 (46.0%)	6780 (55.5%)	Fisher's exact test
				Odds Ratio:
				0.554 (95% CI 0.511-
				0.600)
Median LOS (Days)	5.8	5.0	5.3	<i>P</i> <0.0001
				Mann-Whitney
Max Respiratory Support				
ECMO	11 (0.3%)	7 (0.3%)	18 (0.3%)	<i>P</i> <0.0001

It is made available under a CC-BY-NC-ND 4.0 International license .

Mechanical Ventilation	346 (10.4%)	167 (7.9%)	513 (9.4%)	Chi-square
Non-Invasive Ventilation	346 (10.4%)	188 (8.9%)	534 (9.8%)	
High Flow Oxygen	946 (28.5%)	403 (19.0%)	1349 (24.8%)	
Low Flow Oxygen	1113 (33.5%)	876 (41.3%)	1989 (36.6%)	
Room Air	559 (16.8%)	479 (22.6%)	1038 (19.1%)	
Mortality				
Alive	7985 (96.2%)	3760 (95.8%)	11745 (96.1%)	<i>P=</i> 0.2707
Deceased	312 (3.8%)	164 (4.2%)	476 (3.9%)	Fisher's exact test
				Odds Ratio:
				0.896 (95% CI 0.739-
				1.087)
Median PCR Cycle Thresho	ld			I
Abbott Alinity	20.71	25.57	n=4070	<i>P</i> <0.0001
	n=2659	n=1411		Mann-Whitney
Hologic Panther	21.30	26.05	n=1282	<i>P</i> <0.0001
	n=(808)	n=(474)		Mann-Whitney
Vaccine				
No vaccine	6191 (74.6%)	3526 (89.9%)	9717 (79.5%)	<i>P</i> ⊲0.0001
>7 days past 1st vaccine	161 (1.9%)	156 (4.0%)	317 (2.6%)	Chi-square
>14 days past 2nd vaccine	1945 (23.4%)	242 (6.2%)	2187 (17.9%)	
				1

601

Data include 12,221 unique patients with high-quality sequence results between March 15, 2021 and August 26,

602 2021. BMI: body mass index; CI: confidence interval; ECMO: extracorporeal membrane oxygenation; LOS: length of

603 stay

604

It is made available under a CC-BY-NC-ND 4.0 International license .

Table 2. Comparison of pertinent patient metadata for 9,693 unique Delta VOC

607 and Alpha VOC patients

	Delta Variant	Alpha Variant	Total	Statistical Analysis
No. (%) with data	8297 (71.8%)	3262 (28.2%)	11559	
Patient Characteristics				<u> </u>
Median Age (Years)	47.3	49.4	48.0	<i>P</i> <0.0001
				Mann-Whitney
Female	4390 (52.9%)	1708 (52.4%)	6098 (52.8%)	<i>P</i> =0.6049
Male	3907 (47.1%)	1554 (47.6%)	5461 (47.2%)	Fisher's exact test
Ethnicity				
Caucasian	3648 (44.1%)	1279 (39.4%)	4927 (42.8%)	<i>P</i> <0.0001
Hispanic or Latino	2092 (25.3%)	967 (29.8%)	3059 (26.6%)	Chi-square
Black	1877 (22.7%)	760 (23.4%)	2637 (22.9%)	
Asian	311 (3.8%)	127 (3.9%)	438 (3.8%)	
Native American	14 (0.2%)	12 (0.4%)	26 (0.2%)	
Hawaiian/Pacific Islander	20 (0.2%)	3 (0.1%)	23 (0.2%)	
Unavailable	303 (3.7%)	96 (3.0%)	399 (3.5%)	
BMI				
Median BMI	29.7	30.5	30.0	<i>P</i> <0.0001
	29.1	30.5	30.0	Mann-Whitney
Admission Data				
	0001 (40.00/)			<i>P</i> <0.0001
Admitted	3321 (40.0%)	1737 (53.2%)	5058 (43.8%)	
Not Admitted	4976 (60.0%)	1525 (46.8%)	6501 (56.2%)	Fisher's exact test
				Odds Ratio:
				0.586 (95% CI 0.540-
				0.636)
Median LOS (Days)	5.8	5.1	5.3	<i>P=</i> 0.0004
				Mann-Whitney
Max Respiratory Support	1	1	1	1

It is made available under a CC-BY-NC-ND 4.0 International license .

ECMO	11 (0.3%)	7 (0.4%)	18 (0.4%)	<i>P</i> <0.0001
Mechanical Ventilation	346 (10.4%)	155 (8.9%)	501 (9.9%)	Chi-square
Non-Invasive Ventilation	346 (10.4%)	165 (9.5%)	511 (10.1%)	
High Flow Oxygen	946 (28.5%)	369 (21.2%)	1315 (26.0%)	
Low Flow Oxygen	1113 (33.5%)	714 (41.1%)	1827 (36.1%)	
Room Air	559 (16.8%)	327 (18.8%)	886 (17.5%)	
Mortality				
Alive	7985 (96.2%)	3099 (95.0%)	11084 (95.9%)	<i>P=</i> 0.0030
Deceased	312 (3.8%)	163 (5.0%)	475 (4.1%)	Fisher's exact test
				Odds Ratio:
				0.743 (95% CI 0.612-
				0.902)
Median PCR Cycle Thresho	ld			
Abbott Alinity	20.71	22.43	n=3768	<i>P</i> <0.0001
	n=2659	n=1109		Mann-Whitney
Hologic Panther	21.30	24.20	n=1183	<i>P</i> <0.0001
	n=808	n=375		Mann-Whitney
Vaccine				I
No vaccine	6191 (74.6%)	3000 (92.0%)	9191 (79.5%)	<i>P</i> <0.0001
>7 days past 1st vaccine	161 (1.9%)	134 (4.1%)	295 (2.6%)	Chi-square
>14 days past 2nd vaccine	1945 (23.4%)	128 (3.9%)	2073 (17.9%)	
			1	

608 Data include 11,559 unique patients with high-quality sequence results between January 1, 2021 and August 26,

609 2021. BMI: body mass index; CI: confidence interval; ECMO: extracorporeal membrane oxygenation; LOS: length of

610 stay

611

612

It is made available under a CC-BY-NC-ND 4.0 International license .

Table 3. Summary of pertinent patient metadata for the 2,187 fully vaccinated

615 patients

	Vaccinated	Not Vaccinated	Total	Statistical Analysis					
Median PCR Cycle Threshold									
Abbott Alinity	20.81	22.27	n=4070	<i>P</i> =0.0172					
	n=822	n=3248		Mann-Whitney					
Hologic Panther	22.40	23.30	n=1282	<i>P</i> =0.2009					
	n=277	n=1005		Mann-Whitney					
Admission Data	I	L	I						
Admitted	589 (26.9%)	4852 (48.4%)	5441 (44.5%)	<i>P</i> <0.0001					
Not Admitted	1598 (73.1%)	5182 (51.6%)	6780 (55.5%)	Fisher's exact test					
				Odds Ratio:					
				0.394 (95% CI 0.355-0.436)					
	Delta Variant	Other Variants	Total						
No. (%) with data	1945 (88.9%)	242 (11.1%)	2187						
Admission Data									
Admitted	500 (25.7%)	89 (36.8%)	589 (26.9%)	<i>P</i> =0.0004					
Not Admitted	1445 (74.3%)	153 (63.2%)	1598 (73.1%)	Fisher's exact test					
				Odds Ratio:					
				0.595 (95% CI 0.449-0.787)					

616

617

618







